Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME
- PMID: 16403946
- DOI: 10.1152/ajpheart.00632.2005
Angiotensin-(1-7) prevents development of severe hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME
Abstract
We examined the influence of chronic treatment with ANG-(1-7) on development of hypertension and end-organ damage in spontaneously hypertensive rats (SHR) chronically treated with the nitric oxide synthesis inhibitor L-NAME (SHR-L-NAME). L-NAME administered orally (80 mg/l) for 4 wk significantly elevated mean arterial pressure (MAP) compared with SHR controls drinking regular water (269 +/- 10 vs. 196 +/- 6 mmHg). ANG-(1-7) (24 microg x kg(-1) x h(-1)) or captopril (300 mg/l) significantly attenuated the elevation in MAP due to L-NAME (213 +/- 7 and 228 +/- 8 mmHg, respectively), and ANG-(1-7) + captopril completely reversed the L-NAME-dependent increase in MAP (193 +/- 5 mmHg). L-NAME-induced increases in urinary protein were significantly lower in ANG-(1-7)-treated animals (226 +/- 6 vs. 145 +/- 12 mg/day). Captopril was more effective (96 +/- 12 mg/day), and there was no additional effect of captopril + ANG-(1-7) (87 +/- 5 mg/day). The abnormal vascular responsiveness to endothelin-1, carbachol, and sodium nitroprusside in perfused mesenteric vascular bed of SHR-L-NAME was improved by ANG-(1-7) or captopril, with no additive effect of ANG-(1-7) + captopril. In isolated perfused hearts, recovery of left ventricular function from 40 min of global ischemia was significantly better in ANG-(1-7)- or captopril-treated SHR-L-NAME, with additive effects of combined treatment. The beneficial effects of ANG-(1-7) on MAP and cardiac function were inhibited when indomethacin was administered with ANG-(1-7), but indomethacin did not reverse the protective effects on proteinuria or vascular reactivity. The protective effects of the ANG-(1-7) analog AVE-0991 were qualitatively comparable to those of ANG-(1-7) but were not improved over those of captopril alone. Thus, during reduced nitric oxide availability, ANG-(1-7) attenuates development of severe hypertension and end-organ damage; prostaglandins participate in the MAP-lowering and cardioprotective effects of ANG-(1-7); and additive effects of captopril + ANG-(1-7) on MAP, but not proteinuria or endothelial function, suggest common, as well as different, mechanisms of action for the two treatments. Together, the results provide further evidence of a role for ANG-(1-7) in protective effects of angiotensin-converting enzyme inhibition and suggest dissociation of factors influencing MAP and those influencing end-organ damage.
Similar articles
-
Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-L-arginine methyl ester.J Cardiovasc Pharmacol. 2011 May;57(5):559-67. doi: 10.1097/FJC.0b013e31821324b6. J Cardiovasc Pharmacol. 2011. PMID: 21326110 Free PMC article.
-
Contribution of cytochrome P450 metabolites of arachidonic acid to hypertension and end-organ damage in spontaneously hypertensive rats treated with L-NAME.Auton Autacoid Pharmacol. 2005 Oct;25(4):143-54. doi: 10.1111/j.1474-8673.2005.00343.x. Auton Autacoid Pharmacol. 2005. PMID: 16176445
-
Signal transduction involving Ras-GTPase contributes to development of hypertension and end-organ damage in spontaneously hypertensive rats-treated with L-NAME.Pharmacol Res. 2005 Nov;52(5):401-12. doi: 10.1016/j.phrs.2005.06.001. Epub 2005 Jul 18. Pharmacol Res. 2005. PMID: 16027001
-
Current insights and future perspectives of flavonoids: A promising antihypertensive approach.Phytother Res. 2024 Jun;38(6):3146-3168. doi: 10.1002/ptr.8199. Epub 2024 Apr 14. Phytother Res. 2024. PMID: 38616386 Review.
-
Protective importance of the myogenic response in the renal circulation.Hypertension. 2009 Aug;54(2):393-8. doi: 10.1161/HYPERTENSIONAHA.109.133777. Epub 2009 Jun 22. Hypertension. 2009. PMID: 19546375 Free PMC article. Review. No abstract available.
Cited by
-
Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies.Front Pharmacol. 2024 Aug 21;15:1394997. doi: 10.3389/fphar.2024.1394997. eCollection 2024. Front Pharmacol. 2024. PMID: 39234105 Free PMC article. Review.
-
Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease.Clin Sci (Lond). 2024 Jun 5;138(11):645-662. doi: 10.1042/CS20240249. Clin Sci (Lond). 2024. PMID: 38808486 Free PMC article. Review.
-
Mas receptor: a potential strategy in the management of ischemic cardiovascular diseases.Cell Cycle. 2023 Jul;22(13):1654-1674. doi: 10.1080/15384101.2023.2228089. Epub 2023 Jun 26. Cell Cycle. 2023. PMID: 37365840 Free PMC article. Review.
-
Mitigating Cardiotoxicity of Dendrimers: Angiotensin-(1-7) via Its Mas Receptor Ameliorates PAMAM-Induced Cardiac Dysfunction in the Isolated Mammalian Heart.Pharmaceutics. 2022 Dec 1;14(12):2673. doi: 10.3390/pharmaceutics14122673. Pharmaceutics. 2022. PMID: 36559167 Free PMC article.
-
Involvement of shedding induced by ADAM17 on the nitric oxide pathway in hypertension.Front Mol Biosci. 2022 Oct 14;9:1032177. doi: 10.3389/fmolb.2022.1032177. eCollection 2022. Front Mol Biosci. 2022. PMID: 36310604 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous